{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:55:19Z","timestamp":1794434119098,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000074","name":"U.S. Department of Justice","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020523","name":"United States Drug Enforcement Administration","doi-asserted-by":"publisher","award":["15DDHQ-P-0740"],"award-info":[{"award-number":["15DDHQ-P-0740"]}],"id":[{"id":"10.13039\/100020523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neuropharm.2025.110509","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:36:24Z","timestamp":1747121784000},"page":"110509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effects of novel fentanyl derivatives in rats trained to discriminate morphine"],"prefix":"10.1016","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-7896","authenticated-orcid":false,"given":"Ellen","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidubem","family":"Eneanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teneille W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luli R.","family":"Akinfiresoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110509_bib1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bph.17376","article-title":"Slow dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal at the \u03bc-opioid receptor","volume":"182","author":"Alhosan","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108110","article-title":"In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45","volume":"171","author":"Bilel","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110509_bib3","series-title":"Methods of Behavior Analysis in Neuroscience","author":"Buccafusco","year":"2009"},{"key":"10.1016\/j.neuropharm.2025.110509_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00204-024-03887-z","article-title":"In vivo pharmacokinetic, pharmacodynamic and brain concentration comparison of fentanyl and para-fluorofentanyl in rats","volume":"99","author":"Canfield","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110509_bib6","doi-asserted-by":"crossref","first-page":"13118","DOI":"10.1073\/pnas.1104614108","article-title":"Pathway and mechanism of drug binding to G-protein-coupled receptors","volume":"108","author":"Dror","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110509_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108599","article-title":"Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: differential antagonism by naltrexone","volume":"221","author":"Flynn","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110509_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.121.000912","article-title":"Characterization of the discriminative stimulus effects of binary mixtures of","volume":"380","author":"Flynn","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib10","series-title":"Drug Overdose Deaths in the United States, 2003\u20132023. NCHS Data Brief","author":"Garnett","year":"2024"},{"key":"10.1016\/j.neuropharm.2025.110509_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2621","article-title":"Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone)","volume":"32","author":"Grifell","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-007-0039-1","article-title":"Studies on 1-(2-phenethyl)-4-(N-propionylanilino) piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues","volume":"26","author":"Higashikawa","year":"2008","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1124\/jpet.102.044875","article-title":"Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence","volume":"304","author":"Holtzman","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001525","article-title":"Pharmacokinetic and pharmacodynamic consequences of cytochrome P450 3A inhibition on mitragynine metabolism in rats","volume":"385","author":"Kamble","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bph.15573","article-title":"The anomalous pharmacology of fentanyl","volume":"180","author":"Kelly","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00008877-199605000-00007","article-title":"Contribution of individual differences to discriminative stimulus, antinociceptive and rate-decreasing effects of opioids: importance of the drug's relative intrinsic efficacy at the mu receptor","volume":"7","author":"Morgan","year":"1996","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5055\/jom.2020.0569","article-title":"An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg\/0.5 mL of intramuscular naloxone hydrochloride to 2 mg\/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects","volume":"16","author":"Moss","year":"2020","journal-title":"J. Opioid. Manag."},{"key":"10.1016\/j.neuropharm.2025.110509_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234683","article-title":"Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level","volume":"15","author":"Moss","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110509_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pbr.2015.07.012","article-title":"Animal models for addiction medicine: from vulnerable phenotypes to addicted individuals","volume":"224","author":"Nader","year":"2016","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110509_bib20","article-title":"National and regional trends in fentanyl seizures in the United States, 2017-2023","author":"Palamar","year":"2024","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2018_40","article-title":"Drug discrimination: historical origins, important concepts, and principles","volume":"39","author":"Porter","year":"2018","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110509_bib22","series-title":"Fentanyl StatPearls. StatPearls [Internet]","author":"Ramos-Matos","year":"2025"},{"key":"10.1016\/j.neuropharm.2025.110509_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","article-title":"Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","volume":"150","author":"Schwienteck","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110509_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(25)30571-9","article-title":"Evaluation of the discriminative effects of morphine in the rat","volume":"198","author":"Shannon","year":"1976","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-3565(25)30827-X","article-title":"Further evaluation of the discriminative effects of morphine in the rat","volume":"201","author":"Shannon","year":"1977","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib26","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1021\/acschemneuro.3c00850","article-title":"Structure-activity relationships, deuteration, and fluorination of synthetic cannabinoid receptor agonists related to AKB48, 5F-AKB-48, and AFUBIATA","volume":"15","author":"Sparkes","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110509_bib27","series-title":"Co-involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants, 2011-2021","first-page":"1","author":"Spencer","year":"2023"},{"key":"10.1016\/j.neuropharm.2025.110509_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1213\/ane.0b013e3181605add","article-title":"A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology","volume":"106","author":"Stanley","year":"2008","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2025.110509_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/adar.2022.10280","article-title":"Interaction with the lipid membrane influences fentanyl pharmacology","volume":"2","author":"Sutcliffe","year":"2022","journal-title":"Adv. Drug Alcohol. Res."},{"key":"10.1016\/j.neuropharm.2025.110509_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.120.265561","article-title":"Fentanyl but not morphine interacts with nonopioid recombinant human neurotransmitter receptors and transporters","volume":"374","author":"Torralva","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.119.258566","article-title":"Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis","volume":"371","author":"Torralva","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib32","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0022-3565(24)39167-0","article-title":"Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity","volume":"294","author":"Ulens","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4155\/fmc.13.215","article-title":"Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications","volume":"6","author":"Vardanyan","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110509_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114805","article-title":"Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated","volume":"195","author":"Varshneya","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110509_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173572","article-title":"Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depression","volume":"226","author":"Varshneya","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110509_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","article-title":"Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances","volume":"151","author":"Varshneya","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110509_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173242","article-title":"Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors","volume":"208","author":"Varshneya","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110509_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neuropharm.2019.02.007","article-title":"Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice","volume":"150","author":"Walentiny","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110509_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.121.000689","article-title":"Antinociceptive and discriminative stimulus effects of six novel psychoactive opioid substances in male rats","volume":"379","author":"Walker","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)23869-1","article-title":"In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats","volume":"271","author":"Walker","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110509_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s002130050035","article-title":"Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids","volume":"148","author":"Zhang","year":"2000","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:59:01Z","timestamp":1762214341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":41,"alternative-id":["S0028390825002151"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110509","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of novel fentanyl derivatives in rats trained to discriminate morphine","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110509"}}